KRAS and pancreatic ductal adenocarcinoma: This was also demonstrated recently in pancreatic ductal adenocarcinoma (PDAC); a tumour type that is similarly characterized by activating KRAS (G12V) and CDKN2A mutations (Salvador‐Barbero et al, 2020).